S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

ADMA Biologics Stock Forecast, Price & News

+0.10 (+7.69%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.21 million shs
Average Volume
1.19 million shs
Market Capitalization
$274.14 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Biologics logo

About ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Ramsey, NJ.


Find Strong Cheap Stocks Under $10 to Buy in December
December 7, 2021 |  finance.yahoo.com
Preview: ADMA Biologics's Earnings
November 9, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$42.22 million
Book Value
$0.84 per share


Net Income
$-75.75 million
Net Margins
Pretax Margin




Free Float
Market Cap
$274.14 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.16 out of 5 stars

Medical Sector

420th out of 1,417 stocks

Biological Products, Except Diagnostic Industry

63rd out of 207 stocks

Analyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

Is ADMA Biologics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics
or view top-rated stocks.

How has ADMA Biologics' stock price been impacted by COVID-19 (Coronavirus)?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADMA shares have decreased by 39.4% and is now trading at $1.40.
View which stocks have been most impacted by COVID-19

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for ADMA Biologics

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The biotechnology company earned $20.68 million during the quarter, compared to analysts' expectations of $18.58 million. ADMA Biologics had a negative trailing twelve-month return on equity of 71.69% and a negative net margin of 108.60%. During the same quarter in the previous year, the business posted ($0.19) earnings per share.
View ADMA Biologics' earnings history

What price target have analysts set for ADMA?

5 analysts have issued 1 year price targets for ADMA Biologics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect ADMA Biologics' share price to reach $5.70 in the next year. This suggests a possible upside of 307.1% from the stock's current price.
View analysts' price targets for ADMA Biologics
or view top-rated stocks among Wall Street analysts.

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:
  • Adam S. Grossman, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Brian Lenz, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Kaitlin Kestenberg, Vice President-Compliance & Clinical Operations
  • Lucy DeMario, Senior Director-Scientific & Data Analysis
  • Michael Least, Vice President-Market Access & National Accounts

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include First Hawaiian Bank (0.26%) and XR Securities LLC (0.00%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends for ADMA Biologics

Which major investors are buying ADMA Biologics stock?

ADMA stock was purchased by a variety of institutional investors in the last quarter, including First Hawaiian Bank. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc, and Young Kwon.
View insider buying and selling activity for ADMA Biologics
or or view top insider-buying stocks.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $1.40.

How much money does ADMA Biologics make?

ADMA Biologics has a market capitalization of $274.14 million and generates $42.22 million in revenue each year. The biotechnology company earns $-75.75 million in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does ADMA Biologics have?

ADMA Biologics employs 407 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is www.admabiologics.com.

Where are ADMA Biologics' headquarters?

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at (201) 478-5552, via email at [email protected], or via fax at 201-478-5553.

This page was last updated on 1/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.